| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TG-101348 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.5 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.019 | 0.5 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |